We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Strategic, or strategically confused?

9 Jun 2006 By Robert Cyran

In March, the German drug maker abandoned its hostile bid for competitor Schering after Bayer emerged as a white knight. In April, Merck said it wouldn t be a longterm shareholder. Yet it has now doubled its stake in Schering to more than 10%. What’s it up to?

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)